Vitamin D insufficiency may not represent a clear indicator of bone disease in community-dwelling patients, according to a recent review examining biochemical, structural, and clinical evidence linking low vitamin D levels to fracture risk and bone health.
In the review published in Pathology, researchers assessed whether commonly used thresholds for vitamin D deficiency and insufficiency are consistently associated with measurable abnormalities in bone metabolism, bone structure, or fracture outcomes. The investigators reported that many patients with low serum vitamin D levels did not demonstrate clear biochemical or structural indicators of bone disease.
The researchers evaluated serum levels of 25-hydroxyvitamin D (25[OH]D), the primary biomarker used to assess vitamin D status. Commonly used thresholds include levels below 30 nmol/L and between 30 and either 50 or 75 nmol/L, although these cutoffs vary and were not originally established based on clear evidence of bone disease.
To investigate this question, the Australia-based team examined data from large population studies evaluating biochemical markers associated with bone metabolism. In one cohort of 11,855 community-dwelling participants, 1,439 had 25(OH)D levels below 30 nmol/L. Among that subgroup, relatively few patients showed biochemical abnormalities traditionally associated with deficiency: about 6% had low serum calcium, approximately 3% had low phosphate levels, and just over one-third had elevated parathyroid hormone levels.
These findings suggest that many patients classified as vitamin D deficient based on laboratory thresholds do not display laboratory evidence of bone disease.
The investigators also evaluated structural bone outcomes. Vitamin D deficiency is theorized to impair bone mineralization, potentially leading to osteomalacia or structural deterioration. However, analyses of bone biopsy data and imaging studies have not consistently demonstrated clear associations between vitamin D levels and reduced bone mineral density or microarchitectural deterioration.
For example, one prior study examining postmortem bone samples from more than 600 patients found minimal evidence of osteomalacia even among those with lower vitamin D concentrations, with only a small minority showing histologic signs of defective mineralization.
The researchers also reviewed randomized controlled trials and meta-analyses evaluating vitamin D supplementation and fracture prevention. Evidence across these studies was mixed. Some trials reported modest reductions in fracture risk, particularly among older institutionalized patients receiving both vitamin D and calcium supplementation. In one intervention study involving nursing home residents with relatively low baseline vitamin D levels, supplementation with vitamin D and calcium was associated with fewer hip and nonvertebral fractures.
However, many trials conducted in community-dwelling patients did not demonstrate statistically significant reductions in fracture risk with vitamin D supplementation alone. Large randomized studies, including the Vitamin D and Omega-3 Trial (VITAL) and the DO-HEALTH study, reported no meaningful difference in fracture incidence between patients receiving vitamin D supplements and those receiving placebo.
Some high-dose vitamin D regimens were associated with increased fracture risk. Two trials evaluating annual high-dose vitamin D administration reported higher rates of falls or fractures in certain populations, raising questions about the safety of large intermittent doses.
Overall, the investigators concluded that evidence supporting widespread screening or supplementation in otherwise healthy community populations remains limited. Instead, targeted testing and treatment may be most appropriate for patients at higher risk of deficiency-related bone disease, such as those living in nursing homes or patients with limited sun exposure, malnutrition, or malabsorption disorders.
The researchers emphasized that future studies should focus on identifying vitamin D thresholds that reliably indicate bone disease and determining whether supplementation improves clinically meaningful outcomes in patients with confirmed deficiency.
The researchers reported no conflicts of interest and no specific funding for the study.
Source: Pathology
